This site is intended only for healthcare professionals resident in Egypt

Search

Menu

Close

Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usAsk a questionPfizer medical information

Menu

Close

Suspect & Detect About ATTR-CM Study Design Efficacy & Safety Profile Dosing MOD/MOA Important Safety Information Abbreviated Prescribing Information
MOD/MOA

ATTR-CM MOD

ATTR-CM MOA

ATTR amyloidosis is caused by TTR protein destabilization - not due to the production of TTR itself2

TTR protein plays an important role in the body - it is vital to some
biologic functions including the transport of thyroxine and retinol 3

ATTR-CM: transthyretin amyloid cardiomyopathy; MOA: mechanism of action; MOD: mechanism of disease; TTR: transthyretin.

References:VYNDAMAX™ (Tafamidis) Egyptian Drug Authority leaflet approval date 26/7/2021. Revision date: June 2021. Judge DP, Heitner SB, Falk RH, et al. Transthyretin stabilization by AG1O in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2019;74(3):285-295.Vieira M, Saraiva MJ. Transthyretin: a multifaceted protein. Biomol Concepts. 2014;5(1):45-54. Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86(9):1036-1043.Coelho T, Merlini G, Bulawa CE, et al. Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurol Ther. 2016;5(1):1-25.

VYNDAMAX™ is an approved treatment that specifically targets TTR destabilization
- the cause of disease pathogenesis - and fortifies the TTR tetramer to protect its
natural role3






























ATTR-CM: transthyretin amyloid cardiomyopathy; MOA: mechanism of action; MOD: mechanism of disease; TTR: transthyretin.

References:VYNDAMAX™ (Tafamidis) Egyptian Drug Authority leaflet approval date 26/7/2021. Revision date: June 2021.Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neural, Neurosurg Psychiatry. 2015;86(9):1036-1043. Monteiro C, Martins da Silva A, Ferreia N, et al. Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p. TTRV50M) amyloidosis patients. Amyloid. 2018;25(2):120-128.Maurer MS, Elliott P, Merlini G, et al. Design and rationale of the phase 3 ATTR-ACT clinical trial (tafamidis in transthyretin cardiomyopathy clinical trial). Circ Heart Fail. 2017;10(6):e003815.Bulawa CE, Connelly S, DeVit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109(24):9629-9634.

MOH Approval No. : HF0098OA171/082022

Invalidation Date : 11/08/2024

PP-VDM-EGY-0011

Support & Services

Dosing

Click HereLoading
Resources Click HereLoading

Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries. 


Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.


PP-UNP-EGY-0241
You are leaving the Pfizer for Professionals website
​You are being directed to a third-party website.

Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.
 
PP-UNP-EGY-0241
For Healthcare Professionals only

These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
 

If you select ‘No’, you will be redirected to Pfizer.com, the global Pfizer website.
 

I confirm that I am a healthcare professional resident in Egypt.
 

PP-UNP-EGY-0241

Yes No
You are leaving the Pfizer for Professionals website You are being directed to a third-party website.

Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.

PP-UNP-EGY-0241